Baseline and demographic characteristics
Characteristic . | No. . |
|---|---|
| Demographics | |
| Age, y (range) | 37.5 ± 14.7 (18-55) |
| Weight, kg | 83.1 ± 8.8 |
| Race | 12 white, 1 black |
| HIV and HCV status (%) | |
| HIV, no. with positive serology | 5/13 (38) |
| HCV, no. with positive serology | 13/13 (100) |
| FVIII treatment schedule (%) | |
| Prophylactic | 1/13 (8) |
| On demand | 12/13 (92) |
| FVIII therapy in past 12 months (range) | |
| Number of infusions | 50 ± 40.5 (10-150) |
| FVIII usage, units | 117 076 ± 52 000 (12-450 000) |
| Spontaneous bleeding episodes per month (range) | 3.7 ± 2.6 (0.5-8.0) |
| Functional status (%) | |
| Work or attend school | 8/13 (62) |
| Disabled, hemophilia related | 5/13 (39) |
Characteristic . | No. . |
|---|---|
| Demographics | |
| Age, y (range) | 37.5 ± 14.7 (18-55) |
| Weight, kg | 83.1 ± 8.8 |
| Race | 12 white, 1 black |
| HIV and HCV status (%) | |
| HIV, no. with positive serology | 5/13 (38) |
| HCV, no. with positive serology | 13/13 (100) |
| FVIII treatment schedule (%) | |
| Prophylactic | 1/13 (8) |
| On demand | 12/13 (92) |
| FVIII therapy in past 12 months (range) | |
| Number of infusions | 50 ± 40.5 (10-150) |
| FVIII usage, units | 117 076 ± 52 000 (12-450 000) |
| Spontaneous bleeding episodes per month (range) | 3.7 ± 2.6 (0.5-8.0) |
| Functional status (%) | |
| Work or attend school | 8/13 (62) |
| Disabled, hemophilia related | 5/13 (39) |